Cancer Prevention and Control Clinical Trials Planning Grant Program (U34 Clinical Trials Optional)
ID: 341389Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $600K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/341389

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-22-174.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering the Cancer Prevention and Control Clinical Trials Planning Grant Program (U34), aimed at supporting well-planned clinical trials that enhance cancer prevention and control measures. This program seeks to address critical gaps in understanding study populations, intervention feasibility, and clinical trial design prior to full-scale trials, thereby improving trial efficiency and effectiveness through stakeholder engagement. Funding is available for up to $225,000 per year for a maximum project period of three years, with applications due by September 7, 2025. Interested applicants are encouraged to consult with NCI staff before submission and can find more information at the provided link or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.

    Point(s) of Contact
    OERWebmaster03@od.nih.gov
    Files
    Title
    Posted
    PAR-22-174-Full-Announcement.html
    PAR-22-174.html
    The Department of Health and Human Services, through the National Cancer Institute (NCI), announces the Cancer Prevention and Control Clinical Trials Planning Grant Program (U34). This funding initiative aims to support well-planned clinical trials focused on enhancing cancer prevention and control measures. The U34 mechanism enables research teams to gather critical data addressing gaps in study population understanding, intervention feasibility, and clinical trial design prior to full-scale trials. The program facilitates stakeholder engagement to ensure diverse and representative study populations, ultimately improving trial efficiency and effectiveness. Funding is available for up to $225,000 per year, with a maximum project period of three years. Eligible applicants include various educational and nonprofit institutions as well as state and local governments. The application process requires adherence to strict guidelines and includes essential milestones, stakeholder engagement plans, and a description of future clinical trials. The program emphasizes the necessity of completing consultations with NCI staff prior to submission, aligning projects with NCI’s mission to foster impactful cancer research.
    Similar Opportunities
    Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the Cancer Prevention and Control Clinical Trials Planning Grant Program (R34), aimed at enhancing clinical trials focused on cancer prevention and control. This program seeks to address critical gaps in knowledge regarding study populations, interventions, and operational challenges, facilitating the collection of essential data to finalize protocols for future clinical trials. The initiative is particularly important for improving cancer-related health behaviors, screening, and the long-term outcomes of cancer survivors. Eligible applicants include a diverse range of organizations, with funding available up to $600,000 over three years, and applications are due by September 7, 2025. For further inquiries, interested parties can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering the Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required) to support investigator-initiated clinical trials aimed at reducing the burden of cancer. This funding opportunity focuses on enhancing early detection, prevention, healthcare delivery, and survivorship improvements, explicitly excluding studies related to cancer diagnosis or oncologic therapies. Eligible applicants include a diverse range of organizations such as higher education institutions, nonprofits, and tribal organizations, with applications due by 5:00 PM local time on January 5, 2024, and a maximum project period of five years. For further details, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the program's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-24-072.html.
    Pragmatic Trials across the Cancer Control Continuum (UG3/UH3 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Pragmatic Trials across the Cancer Control Continuum" (UG3/UH3), aimed at accelerating the development of evidence-based cancer interventions that reflect the diversity of the U.S. population. This initiative seeks applications that propose interventions designed to improve cancer-related outcomes through pragmatic trial designs, with a particular focus on addressing health disparities among underrepresented populations. The funding opportunity allows for a total of up to $500,000 annually for the UG3 phase and $750,000 for the UH3 phase, with applications accepted until November 17, 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the R21 Clinical Trial Optional mechanism, aimed at supporting exploratory and developmental research in cancer diagnosis, treatment, imaging, symptom management, and prevention. This grant is designed to encourage innovative studies that challenge existing paradigms and address critical barriers in cancer research, particularly focusing on reducing disparities among underserved populations. Eligible applicants include a wide range of organizations, such as historically black colleges, tribal governments, and faith-based organizations, with a maximum funding amount of $275,000 available over a two-year period. Interested parties can find more information and application details at the provided link, with a submission deadline of July 1, 2025, and inquiries directed to the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Discovery and Development of Natural Products for Cancer Interception and Prevention (UG3/UH3 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Discovery and Development of Natural Products for Cancer Interception and Prevention" under the cooperative agreement mechanism. This initiative aims to support innovative projects that focus on the discovery and development of novel natural products that are safe, nontoxic, and effective in intercepting or preventing cancer, with a structured approach divided into two phases: the UG3 phase for initial target selection and assay validation, followed by the UH3 phase for large-scale evaluations and pharmacokinetic assessments. The total funding available for this program is $4.5 million over the fiscal years 2024 to 2026, with a deadline for applications set for June 14, 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Discovery and Development of Natural Products for Cancer Interception and Prevention (UG3/UH3 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the Discovery and Development of Natural Products for Cancer Interception and Prevention, specifically through a cooperative agreement mechanism. This initiative aims to support the discovery and development of novel, safe, and effective natural products that target cancer prevention, structured in two phases: the UG3 phase for initial screenings and assay development lasting up to three years, followed by the UH3 phase for full-scale evaluations lasting up to two years. The program emphasizes the importance of high-throughput screening strategies and collaboration with existing NCI natural product libraries, with a total funding allocation of $4.5 million for approximately 12 awards. Interested applicants must submit their proposals by June 13, 2025, and can direct inquiries to grantsinfo@nih.gov for further information.
    Cancer Immunoprevention Network (CIP-Net) Resource Coordinating Center (U24 Clinical Trials Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity to establish the Cancer Immunoprevention Network (CIP-Net) Resource Coordinating Center (CIP-Net DRCC) through a cooperative agreement. This initiative aims to enhance collaborative research in cancer immunoprevention by providing data coordination, scientific outreach, and support for early career scientists, while also mandating a Plan for Enhancing Diverse Perspectives (PEDP) to promote inclusivity. Eligible organizations can apply for funding of up to $499,999 annually for a maximum of five years, with a total of $850,000 allocated for one award in FY 2025. Interested applicants must submit their proposals by December 2, 2024, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE) (U54 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE)" aimed at fostering collaborations between institutions serving underserved populations and NCI-designated Cancer Centers. The initiative seeks to enhance cancer research capacity, promote workforce diversity, and implement community outreach initiatives to address cancer health disparities. This program is vital for developing comprehensive research projects that include administrative cores, research education, and outreach efforts, ultimately contributing to a stronger national cancer program. Eligible applicants can request funding of up to $2.2 million over five years, with the application submission period starting on December 15, 2023. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    NCI Small Grants Program for Cancer Research for Years 2023, 2024, and 2025 (NCI Omnibus) (R03 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced the NCI Small Grants Program for Cancer Research (R03) for the years 2023 to 2025. This funding opportunity is designed to support small-scale research projects on cancer that can be completed within a two-year timeframe and with limited resources, including pilot studies, secondary data analyses, and the development of research methodologies or technologies. Grants of up to $50,000 per year are available to a wide range of eligible applicants, including higher education institutions, nonprofits, and various community organizations. Interested parties should submit their applications electronically via Grants.gov, with the first submission deadline having been January 22, 2023, and subsequent deadlines continuing through 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    NIAID Clinical Trial Planning Grant (R34 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Allergy and Infectious Diseases (NIAID), has announced a funding opportunity for the Clinical Trial Planning Grant (R34), aimed at supporting the planning and preparation necessary for investigator-initiated clinical trials. This grant encourages applications that focus on high-priority research aligned with NIAID's mission, providing funding of up to $150,000 for activities such as protocol development, study team establishment, and regulatory approvals. The opportunity is open to a diverse range of eligible applicants, including educational institutions, nonprofits, and governmental entities, with applications evaluated based on significance, innovation, and the research environment. Interested applicants should note that the application deadline is May 13, 2026, and can find more information at the provided NIH grants link or by contacting NIH Grants Information at grantsinfo@nih.gov.